Molecular Role of SGK3 Gene in Promoting the Progression of Non-small Cell Lung Cancer

Miao Li, Qingyu Yang, Rui YanInternational Journal of Biology and Life Sciences 2024 · DOI

Abstract

Objective: To investigate the role of SGK3 in the progression of non-small cell lung cancer (NSCLC) and its effect on cell growth using lung cancer cell lines. Method: A retrospective analysis was conducted on 134 NSCLC patients diagnosed between January 2014 and December 2018, including 83 cases of adenocarcinoma and 51 cases of squamous cell carcinoma. Immunohistochemical staining was used to assess SGK3 expression levels and analyze correlations with clinical data. Cellular validation was performed using the A549 cell line. Result: SGK3 was significantly overexpressed in lung cancer tissue (P < 0.05). Expression levels correlated significantly with TNM staging and lymph node metastasis (P < 0.05) but not with age or gender. Functional assays (CCK-8, scratch, and invasion) demonstrated that SGK3 promotes cell growth and motility. Conclusion: SGK3 is highly expressed in NSCLC and facilitates cell proliferation and division, suggesting its involvement in disease progression.

Introduction

Non-Small Cell Lung Cancer (NSCLC) accounts for over 80% of all lung cancer cases and remains a leading cause of global mortality. While targeted therapies have improved outcomes, the molecular landscape of NSCLC is complex, and resistance often develops. This study focuses on SGK3 (Serum and Glucocorticoid Kinase-3), a downstream effector of the PI3K signaling pathway. While SGK3's role is known in other cancers, its specific impact on NSCLC progression and metastasis requires deeper investigation to evaluate its potential as a therapeutic target.

Methods

The researchers employed a dual-track approach combining clinical retrospective analysis with in vitro cellular experiments. Tissue specimens from 134 NSCLC patients were examined using Immunohistochemistry (IHC) to score SGK3 expression. Functional validation was performed using the A549 lung cancer cell line treated with a specific inhibitor (PROTAC SGK3 grader-1). Proliferation was measured via CCK-8 assay over five days, while migration and invasion were evaluated using scratch and transwell assays, respectively.

Results

Clinical Correlation

SGK3 expression was significantly higher in advanced cancer stages. In Stage III/IV patients, the SGK3 positive rate was 93.1%, compared to 71.3% in Stage I/II. Similarly, patients with lymph node metastasis exhibited an 87.5% positive rate versus 59.6% in those without. These findings suggest SGK3 is a driver of disease severity rather than just a marker of presence.

Impact on Cell Proliferation and Motility

Inhibition of SGK3 resulted in a marked reduction in cell growth. Treatment with the SGK3 inhibitor reduced cell proliferation significantly by the end of the five-day observation period.

Figure 1: CCK-8 assay results showing the growth inhibition of A549 cells over five days following SGK3 inhibition.

Furthermore, the ability of cancer cells to migrate and invade was significantly impaired. Scratch assays showed a slower healing rate in the inhibited group, and invasion assays revealed a substantial decrease in the number of cells capable of penetrating the physical barrier compared to controls.

Figure 4: Qualitative and quantitative results of scratch (migration) and transwell (invasion) assays at 0h and 48h.

Conclusion

This study identifies SGK3 as a significant promoter of NSCLC progression. Its overexpression in advanced stages and its functional necessity for cell growth and metastasis position it as a promising target for future drug development. Future work will involve in vivo validation and a broader mapping of the regulatory networks influenced by the PI3K/SGK3 axis.

Summary updated

Abstract

Objective: To investigate the role of SGK3 in the progression of non-small cell lung cancer and investigate its effect on cell growth using lung cancer cell lines. Method: A retrospective analysis was conducted on 134 non-small cell lung cancer patients diagnosed in our hospital from January 2014 to December 2018, including 83 cases of adenocarcinoma and 51 cases of squamous cell carcinoma. Immunohistochemical staining was used to divide lung cancer specimens from patients into SGK3 negative and positive groups, and the correlation between SGK3 expression and clinical data was analyzed. Subsequently, cellular level experimental validation was carried out using the A549 lung cancer cell line. Result: Clinical data confirmed that SGK3 was significantly overexpressed in lung cancer tissue (P&lt;0.05), and the difference in its expression level was not related to factors such as age and gender of SGK3 patients, but only showed a significant correlation with TNM staging and lymph node metastasis (P&lt;0.05). In addition, through CCK-8 cell growth rate measurement experiments and cell scratch and invasion experiments, it is speculated that the above clinical findings may be due to the pro cancer effect of SGK3. Conclusion: SGK3 is highly expressed in cancer tissues of non-small cell lung cancer patients. SGK3 promotes lung cancer cell growth and division, suggesting that this regulatory factor may be involved in the occurrence and development of non-small cell lung cancer.
BibTeX
@article{li2024molecular,
  author = {Miao Li and Qingyu Yang and Rui Yan},
  title = {{Molecular Role of SGK3 Gene in Promoting the Progression of Non-small Cell Lung Cancer}},
  journal = {International Journal of Biology and Life Sciences},
  year = {2024},
  doi = {10.54097/g937df95},
}
Figure